Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.
Videos
Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.
Mary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.
Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.
Dr Mary Mulcahy, a key opinion leader, describes the efficacy and safety outcomes of the EPOCH clinical trial.
The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.
Dr Mary Mulcahy explains the rationale and study design of the phase III EPOCH clinical trial.
Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.
Dr Mary Mulcahy, an expert oncologist, details how radioembolization is involved in the treatment of colorectal cancer with liver metastasis.
Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.
Nino Balanchivadze, MD, FACP, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer in relation to the race of patients.
Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.
Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.
Mary F. Mulcahy, MD, describes the treatment options available for colorectal cancer with liver metastasis in the first and second line.
Alice S. Mims, MD, Acute Leukemia Clinical Research director and associate professor in the Division of Hematology at Ohio State University Comprehensive Cancer Center, discusses key updates to the National Comprehensive Cancer Network guidelines on newly-diagnosed acute myeloid leukemia.
Catherine Callaghan Coombs, MD, discusses 2 upcoming trials in chronic lymphocytic leukemia.
Tom Hutson, DO, PharmD, reviews the case of a 59-year-old woman with metastatic renal cell carcinoma, with intermediate risk and the role of risk assessment in patient management.
Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.
A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.
A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.
Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.
Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.
Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.
Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.
Irene Ghobrial, MD discusses multiple trials and their significance for treating patients with smoldering multiple myeloma and newly diagnosed multiple myeloma.
Neeraj Agarwal, MD, discusses the PSA response rate and adherence rate of a real-world study of apalutamide in patients with prostate cancer across 63 United States urology practices.
Erika P. Hamilton, MD, discusses unmet needs in treatment options for platinum-resistant ovarian cancer due to the challenges of screening, and what treatment options may become viable in the future.
John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.